Signatera, a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer. It is designed to track 16 patient-specific somatic variants. Signatera is the first ctDNA test custom-built for each patient based on the unique mutations in an individual patient's tumor. Signatera has been shown in numerous clinical studies, across non-small cell lung, bladder, breast and colorectal cancers, to identify molecular residual disease significantly earlier (up to two years earlier) than standard imaging. Signatera is available in China under the Chinese brand name "Tumor MRD Customized Detection (HuaJianWei for short)."
Bladder Cancer, Breast Cancer, Colorectal Cancer, Non Small Cell Lung Cancer